Associated Papers
Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status.
Bittner M et al.
International Journal of Molecular Sciences, 2026
41751910 (PubMed )
Supplement: ijms-27-01774-s001.zip › Tables_Suppl_Carey_MS_2025_Revised_20260129.xlsx › Suppl_Table_5
Select a paper to view details